An Objective Comparison Between Bivalirudin and Heparin During Peripheral Vascular Interventions

References

• Hirsch AT , CriquiMH, Treat-JacobsonDet al. Peripheral arterial disease detection, awareness, and treatment in primary care . JAMA286, 1317 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Adam DJ , BeardJD, ClevelandTet al. Bypass Versus Angioplasty in Severe Ischemia of the Leg (BASIL): multicenter, randomized controlled trial . Lancet366 ( 9501 ), 1925 – 1934 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Weitz JI , HudobaM, MasselD, MaraganoreJ, HirshJ . Clot bound thrombin is protected from inhibition by heparin–antithrombin III but is susceptible to inactivation by antithombin III independent inhibitors . J. Clin. Invest.86, 385 ( 1990 ).
   PubMed Web of Science ®Google Scholar
• Eitzman DT , ChiL, SagganL, SchwartzRS, LucchesiBR, FayWP . Heparin neutralization by platelet rich thrombi. Role of platelet factor 4 . Circulation89, 1523 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Lefkovits J , TopolEJ . Direct thrombin inhibitors in cardiovascular medicine . Circulation90, 1552 ( 1994 ).
   PubMed Web of Science ®Google Scholar
• Xiao X , TherouxP . Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor . Circulation97, 251 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Warkentin TE , SheppardJA, SigouinCS, KohlmannT, EichlerP, GreinacherA . Imbalance and risk factor interactions in heparin-induced thrombocytopenia . Blood108, 2937 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Ortel TL . Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation . Hematol. Am. Soc. Hematol. Educ. Progr.225 – 232 ( 2009 ).
   PubMedGoogle Scholar
• Warkentin TE , KeltonJG . A 14-year study of heparin-induced thrombocytopenia . Am. J. Med.101 ( 5 ), 502 – 507 ( 1996 ).
   PubMed Web of Science ®Google Scholar
• Nand S , WongW, YuenBet al. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcome in 108 consecutive patients treated at a single institution . Am. J. Hematol.56 ( 1 ), 12 – 16 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Schmitt BP , AdelmanB . Heparin-associated thrombocytopenia: a critical review and pooled analysis . Am. J. Med. Sci.305 ( 4 ), 208 – 215 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Smythe MA , KoerberJM, MattsonJC . The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital . Chest131 ( 6 ), 1644 – 1649 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Eres A . Use of bivalirudin as the foundation anticoagulant during percutaneous peripheral interventions . J. Invasive Cardiol.18, 125 – 128 ( 2006 ).
   PubMedGoogle Scholar
• Allie D , HallP, ShammasNWet al. The Angiomax Peripheral Procedure Registry of Vascular Events trial (APPROVE): in-hospital and 30-day results . J. Invasive. Cardiol.16, 651 – 656 ( 2004 ).
   PubMedGoogle Scholar
• Fox I , DawsonA, LoyndsPet al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans . Thromb. Heamost.69, 157 – 163 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Lee CJ , AnsellJE . Direct thrombin inhibitors . Br. J. Clin. Pharmacol.72 ( 4 ), 581 – 592 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Allie DE , LitzmanMD, WyattCHet al. Bivalirudin as a foundation anticoagulant in peripheral vascular disease disease: a safe and feasible alternative for renal and iliac interventions . J. Invasive Cardiol.15, 334 – 342 ( 2003 ).
   PubMedGoogle Scholar
• Katzen BT , ArdidMI, MacLeanAAet al. Bivalirudin as an anticoagulant agent: safety and efficacy in peripheral interventions . J. Vasc. Interv. Radiol.16, 1183 – 1187 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Lincoff A , BittlJ, HarringtonRet al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: Replace-2 Randomized trial . JAMA289, 853 – 863 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Kastrati A , NeumannF-J, SchulzSet al. Abciximab and heparin versus bivalirudin for non-ST elevation myocardial infarction . N. Engl. J. Med.365, 1980 – 1989 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Stone GW , McLaurinB, CoxDet al. Bivalirudin for patients with acute coronary syndromes . N. Engl. J. Med.355, 2203 – 2216 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Stone GW , WitzenbichlerB, GuagliumiGet al. Bivalirudin during primary PCI in acute myocardial infarction . N. Engl. J. Med.358, 2218 – 3220 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Shammas NW , LemkeJH, DippelEJ . Bivalirudin in peripheral vascular interventions: a single center experience . J. Invasive Cardiol.15, 401 – 404 ( 2003 ).
   PubMedGoogle Scholar
• Shammas NW , LemkeJH, DippelEJet al. In-hospital complications of peripheral vascular interventions using fractionated heparin as the primary anticoagulant . J. Invasive Cardiol.15, 242 – 246 ( 2003 ).
   PubMedGoogle Scholar
• Sheikh IR , AhmedSH, MoriN . Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in percutaneous peripheral intervention . JACC2, 871 – 876 ( 2009 ).
   Google Scholar
• Wayangankar SA , Abu-FadelMS, AronowHDet al. Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting . Circ. Cardiovasc. Interv.6 ( 2 ), 131 – 138 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Stabile E , SorropagoG, TesorioTet al. Heparin versus bivalirudin for carotid artery stenting using proximal endovascular clamping for neuroprotection: results form a prospective randomized study . J. Vasc. Surg.52 ( 6 ), 1505 – 1510 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Joseph L , CasanegraAI, DhariwalMet al. Bivalirudin for the treatment of patients with confirmed or suspected heparin induced thrombocytopenia . J. Thromb. Haemost.26, doi:10.1111/jth.12592 ( 2014 ) ( Epub ahead of print ).
   Google Scholar
• Salemi A , AgrawalYP, FontesMA . An assay to monitor bivalirudin levels on cardiopulmonary bypass . Ann. Thorac. Surg.92 ( 1 ), 332 – 334 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Koster A , ChewD, GrundelMet al. Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass . Anesth. Analg.96, 383 – 386 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Kashyap VS , BishopPD, BenaJFet al. A pilot, prospective evaluation of a direct thrombin inhibitor, bivalirudin (Angiomax), in patients undergoing lower extremity bypass . J. Vasc. Surg.52 ( 2 ), 369 – 374 ( 2010 ).
   PubMed Web of Science ®Google Scholar